Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6036231 | 0.83 | PANK3 (0.32) | EGLN1GRIA1 | |
| SCHEMBL6036147 | 0.82 | CYP11B1 (0.34) | MAPTGRIA1 | |
| SCHEMBL6035787 | 0.82 | CYP11B1 (0.34) | EGLN1KMT2AMAPTGRIA1 | |
| SCHEMBL6034668 | 0.82 | CYP11B1 (0.34) | HRH3GRIA1 | |
| SCHEMBL6035601 | 0.80 | MAPT (0.39) | LMNAKMT2AMAPT | |
| SCHEMBL6034887 | 0.80 | CNR1 (0.37) | LMNAHRH3MAPT | |
| SCHEMBL6035090 | 0.80 | KDM4E (0.39) | EGLN1 | |
| SCHEMBL6216219 | 0.79 | LMNA (0.36) | KCNJ1EGLN1LMNAKMT2AMAPT | |
| SCHEMBL6035846 | 0.77 | PPARG (0.44) | KCNJ1EGLN1LMNAKMT2AMAPT | |
| SCHEMBL6035102 | 0.76 | CNR1 (0.37) | LMNAHRH3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | KCNJ1 737/4885EGLN1 455/4885LMNA 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.